Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

ARA-290

LongevityClinical trialsPubMed records: 25count from PubMed, not curated
Ask Eagle AI about this compound

Overview

O ARA-290 (Cibinetide) é um peptídeo de 11 aminoácidos derivado da eritropoietina (EPO) que ativa seletivamente o Receptor de Reparo Inato (IRR), um heterodímero do receptor de EPO com o receptor β comum. Diferentemente da EPO, o ARA-290 NÃO estimula a produção de glóbulos vermelhos (eritropoiese), fornecendo apenas os efeitos protetores: anti-inflamação, neuroproteção e reparo tecidual. Foi estudado em Fase 2 para sarcoidose e neuropatia. Original in PT-BR

ARA-290 is catalogued under Longevity. 0 Eagle articles in this library reference this compound.

Category
Longevity
Research stage
Clinical trials — Fase 2 (Sarcoidose / Neuropatia) Original in PT-BR
PubMed records
25 (count from PubMed, not curated)
Eagle articles on this compound
0 Eagle articles

Mechanism

Agonista do Receptor de Reparo Inato (IRR) — anti-inflamatório e neuroprotetor SEM efeito eritropoiético Original in PT-BR

O ARA-290 se liga ao IRR (Innate Repair Receptor), um receptor heterodimérico composto por EPOR + βcR. Este receptor é expresso em tecidos sob estresse ou dano, mas NÃO nos precursores eritróides. A ativação do IRR desencadeia: (1) Vias anti-apoptóticas (JAK2/STAT5, PI3K/Akt). (2) Supressão de NF-κB → redução de citocinas inflamatórias. (3) Proteção neuronal contra dano oxidativo e inflamatório. (4) Reparo tecidual sem estimular produção de glóbulos vermelhos. A meia-vida plasmática é extremamente curta (~2 min), mas a sinalização celular persiste por horas-dias. Original in PT-BR

Chemical information

CAS
1208243-50-8
Molecular formula
Undecapeptídeo Original in PT-BR
Molecular weight
~1257 Da
Sequence
Derivado da hélice B da eritropoietina Original in PT-BR
Amino acids
Not recorded in the source.
Solubility
Água bacteriostática Original in PT-BR
Stability
Estável reconstituído por 14 dias refrigerado Original in PT-BR
Half-life
~2 minutos (muito curta — ação via cascata de sinalização) Original in PT-BR
Bioavailability
Alta (SC) Original in PT-BR
Onset
Dias a semanas (neuroproteção) Original in PT-BR
Routes
SC

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

55/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • Melhora significativa da neuropatia em pacientes com sarcoidose Original in PT-BR

    PMID: 25422951Year: 2014Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Identificação do IRR como receptor mediador de proteção tecidual sem eritropoiese Original in PT-BR

    PMID: 22227896Year: 2012Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Demonstrou que peptídeos derivados de EPO podem proteger tecido sem produzir glóbulos vermelhos Original in PT-BR

    PMID: 20846064Year: 2010Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Reação leve no local da injeção
  • Cefaleia transitória

Serious

  • Perfil de segurança favorável nos ensaios clínicos

Contraindications

  • Hipersensibilidade ao composto

Warnings

  • Sem efeito eritropoiético — não confundir com EPO/doping

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for ARA-290.

Lab tests named in the source

  • Hemograma completo
  • PCR
  • VHS
  • Painel neurológico

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Dose Padrão
2-4mg/dia SC Original in PT-BR
Range
1-4mg/dia Original in PT-BR
Frequência
Diário Original in PT-BR

Vial sizes: 5mg — Peptide Calculator

Interactions

These relations come from the imported reference material, which records one label and one comment per pair and no source: no PMID, no population or model, no evidence type and no degree of certainty. Eagle did not verify them and does not endorse them. «Compatible», «Caution» and «Avoid» are the imported material's wording, not an Eagle authorisation or prohibition, and none of this is medical advice.

Reported synergy

Compatible

Related

No Eagle article in this library references this compound yet.

← Back to knowledge area